Draft – Not for Implementation

Content of Human Factors Information in Medical Device Marketing Submissions

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This draft guidance document is being distributed for comment purposes only.

Document issued on December 9, 2022.

You should submit comments and suggestions regarding this draft document within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <u>https://www.regulations.gov</u>. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions about this document, contact OHT3: Office of Gastro-Renal, ObGyn, General Hospital, and Urology Devices/DHT3C: Division of Drug Delivery and General Hospital Devices and Human Factors at (301) 796-5580.

When final, this guidance is intended to be used to complement the FDA guidance "Applying Human Factors and Usability Engineering to Medical Devices," issued February 3, 2016. After reviewing public comment on this draft guidance and upon its finalization, FDA intends to concurrently revise the "Applying Human Factors and Usability Engineering to Medical Devices" guidance, as described herein.



U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health

Draft – Not for Implementation

Preface

Additional Copies

Additional copies are available from the Internet. You may also send an email request to <u>CDRH-Guidance@fda.hhs.gov</u> to receive a copy of the guidance. Please include the document number 1500052 and complete title of the guidance in the request.

Table of Contents

I.	Introduction	. 1
II.	Scope	. 3
III.	Definitions	. 3
IV.	Risk-based approach to human factors engineering information in marketing submissions.	. 5
А	. How to determine HF Submission Category	. 8
В	. What to include in a marketing submission based on HF Submission Category	. 9
V.	Recommended content of human factors information in marketing submissions	11
VI.	Examples	15
А	. Modification to an existing 510(k)-cleared device	15
В	. Modification to an existing PMA-approved device	19
С	. New devices	22

Content of Human Factors Information in Medical Device Marketing Submissions

Draft Guidance for Industry and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

13

1

2

3 4

5

6 7

8

9

10

11 12

14 **I.** Introduction¹

15 FDA is committed to fostering the development of and patient access to innovative medical devices while balancing their benefits and risks. A unique aspect of medical devices is the 16 17 critical role of device-user interface interactions for their safe use. Manufacturers routinely 18 perform human factors assessments of the human-device interface during device development. 19 This guidance provides a risk-based framework to guide manufacturers and FDA staff on the 20 human factors information that should be included in a marketing submission to the Center for 21 Devices and Radiological Health (CDRH) to facilitate the efficiency of the FDA review process. 22 23 The goal of the human factors assessment is to ensure that the device user interface has been 24 designed such that use errors that occur during use of the device that could cause harm or 25 degrade medical treatment are either eliminated or reduced to the extent possible. The main 26 factors to consider in a risk-based approach to human factors assessment, as described in this 27 draft guidance, include the identification of (i.e., presence of or modification to) critical tasks and 28 the elimination or reduction of use-related hazards.

- 29
- 30 This guidance includes recommendations for the content of human factors and usability
- 31 engineering information to be included in marketing submissions.² FDA's decision on a medical

¹ This guidance has been prepared by the Center for Devices and Radiological Health in cooperation with the Office of Combination Products at the Food and Drug Administration.

² In the United States, the term "human factors engineering" is predominant but in other parts of the world,

[&]quot;usability engineering" is preferred. For the purposes of this document, the two terms are considered interchangeable.

Draft – Not for Implementation

32 device marketing submission is based on the applicable statutory and regulatory criteria (e.g.,

33 substantial equivalence for premarket notification (510(k)) submissions, reasonable assurance of

34 safety and effectiveness for premarket approval applications (PMAs) or De Novo classification

35 requests (De Novo requests)). Human factors, to the extent relevant, constitute just one

36 component of FDA's assessment. While FDA believes that it is optimal to minimize use-related

37 risks, it may not be necessary, nor practical, to eliminate all use-related device risks.

38

39 The marketing submission should, where appropriate, demonstrate that the needs of the intended

40 users were considered in the device design and that the device is safe and effective for the

41 intended users, uses, and use environments. Thus, marketing submissions should include, where 42 appropriate information that explains the presence of eritical tasks, validation testing

42 appropriate, information that explains the presence or absence of critical tasks, validation testing
 43 for risk mitigation strategies, and a description of residual risks. Including appropriate human

44 factors information may improve the efficiency of FDA review by reducing the number of

45 requests for additional information.

46

47 After considering stakeholder feedback on the draft guidance "List of Highest Priority Devices

48 <u>for Human Factors Review</u>,"³ FDA has decided that it should issue another draft guidance

49 regarding submission of human factors information for the purposes of premarket review, which

50 will supersede the draft guidance "List of Highest Priority Devices for Human Factors Review."

51

52 When finalized, this draft guidance is intended to be used to complement the FDA guidance

53 "Applying Human Factors and Usability Engineering to Medical Devices"⁴ (hereafter referred to

54 as the Human Factors Guidance). The purpose of the Human Factors Guidance is to recommend

and guide manufacturers through human factors engineering processes during the development

of new medical devices, focusing specifically on the user interface. That guidance provides

57 relevant human factors definitions and recommends useful preliminary analysis and evaluation

58 tools and validation testing that will enable manufacturers to assess and reduce risks associated

59 with medical device use. The purpose of the current guidance is to help manufacturers apply a

risk-based approach when considering what human factors information to include in a marketingsubmission.

61 62

63 After reviewing public comment on this draft guidance and upon its finalization, FDA intends to

64 concurrently revise the Human Factors Guidance to incorporate the definitions included in this

65 guidance, superseding the definitions in Section 3 of the Human Factors Guidance. FDA also

66 intends to concurrently revise the Human Factors Guidance by replacing Section 9

67 "Documentation" and Appendix A "Human Factors and Usability Engineering Report" of the

68 Human Factors Guidance with cross-references to Section V of this guidance, and by making

- 69 any other revisions to the Human Factors Guidance as appropriate.
- 70

³ <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/list-highest-priority-devices-human-factors-review</u>.

⁴ <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices.</u>

Draft – Not for Implementation

- 71 For the current edition of the FDA-recognized consensus standard(s) referenced in this
- 72 document, see the FDA Recognized Consensus Standards Database.⁵ For more information
- regarding use of consensus standards in regulatory submissions, please refer to the FDA
- 74 guidance titled "Appropriate Use of Voluntary Consensus Standards in Premarket Submissions
- 75 <u>for Medical Devices</u>."⁶
- 76

FDA recognizes and anticipates that the Agency and industry may need up to 60 days to perform

activities to operationalize the policies within this guidance. If new information regarding the

79 content of human factors information for marketing submissions is not included in a marketing

- submission received by FDA before or up to 60 days after the publication of the final guidance,
- 81 CDRH staff does not generally intend to request such information during the review of the 82 submission. CDRH does, however, intend to review any such information, if submitted.
- 83
- 84 In general, FDA's guidance documents do not establish legally enforceable responsibilities.
- 85 Instead, guidances describe the Agency's current thinking on a topic and should be viewed only
- 86 as recommendations, unless specific regulatory or statutory requirements are cited. The use of
- the word *should* in Agency guidance means that something is suggested or recommended, butnot required.
- 88 89

90 II. Scope

- 91 This guidance is intended to help submitters and FDA staff determine what human factors
- 92 evaluation information should be included in marketing submissions for medical devices,
- 93 including 510(k)s, De Novo requests, PMAs, including PMA supplements, and humanitarian
- 94 device exemption (HDE) applications.⁷
- 95
- 96 The guidance is not intended to inform manufacturers about how to perform a human factors
- 97 evaluation. This guidance is also not intended to describe when a marketing submission should
- 98 be submitted to legally market a new or modified device.
- 99

100 **III. Definitions**

101 The following definitions⁸ apply for the purposes of this guidance:

⁵ Available at <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm</u>.

⁶ Available at <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices</u>.

⁷ For more information on the human factors evaluation of combination products, see the FDA draft guidance document "<u>Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development</u>," available at <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-factors-studies-and-related-clinical-study-considerations-combination-product-design-and</u>. When final, that guidance will represent FDA's current thinking on the topic thereof.

⁸ The definitions provided in this section are informed by, but not necessarily identical to, the definitions found in the sources that are cited.

Draft – Not for Implementation

102 •	Abnormal use: An intentional act or intentional omission of an act that reflects
103	violative or reckless use or sabotage beyond reasonable means of risk mitigation or
104	control through design of the user interface.
105 •	Critical task: A user task which, if performed incorrectly or not performed at all,
106	would or could cause serious harm to the patient or user, where harm is defined to
107	include compromised medical care.
108 •	Formative evaluation: User interface evaluation conducted with the intent to explore
109	user interface design strengths, weaknesses, and unanticipated use errors. ⁹
• 110	Harm: Injury or damage to the health of people, or damage to property or the
111	environment. ¹⁰
112 •	Hazard: Potential source of harm. ¹¹
113 •	Hazardous situation: Circumstance in which people, property or the environment
114	is/are exposed to one or more hazards. ¹²
115 •	Human factors engineering: Application of knowledge about human behavior,
116	abilities, limitations, and other characteristics to the design of medical devices
117	(including software), systems and tasks to achieve adequate usability. ¹³
118 •	Human factors validation testing: Testing conducted at the end of the device
119	development process to assess user interactions with a device user interface to
120	identify use errors that would or could result in serious harm to the patient or user.
121	Human factors validation testing is also used to assess the effectiveness of risk
122	management measures. Human factors validation testing represents one portion of
123	design validation.
124 •	Normal use: Operation, including routine inspection and adjustments by any user,
125	and stand-by, according to the instructions for use or in accordance with generally
126	accepted practice for those medical devices provided without instructions for use. ¹⁴
127 •	Residual risk : Risk remaining after risk control measures have been implemented. ¹⁵
128 •	Serious harm: Includes both serious injury and death.
129 •	Serious injury: An injury or illness that is life-threatening, results in permanent
130	impairment of a body function or permanent damage to a body structure, or
131	necessitates medical or surgical intervention to preclude permanent impairment of a
132	body function or permanent damage to a body structure. Permanent means

 ⁹ ANSI/AAMI/IEC 62366-1:2015+AMD1:2020 Medical devices—Part 1: Application of usability engineering to medical devices. Formative evaluation is generally performed iteratively throughout the design and development process, but prior to summative evaluation, to guide user interface design as necessary.
 ¹⁰ ANSI/AAMI/ISO 14971 Third Edition 2019-12 Medical devices—Application of risk management to medical

¹⁰ ANSI/AAMI/ISO 14971 Third Edition 2019-12 Medical devices—Application of risk management to medical devices.

¹¹ ANSI/AAMI/ISO 14971 Third Edition 2019-12 Medical devices—Application of risk management to medical devices.

¹² ANSI/AAMI/ISO 14971 Third Edition 2019-12 Medical devices—Application of risk management to medical devices.

¹³ ANSI/AAMI/IEC 62366-1:2015+AMD1:2020 Medical devices—Part 1: Application of usability engineering to medical devices.

¹⁴ *Ibid*.

¹⁵ ANSI/AAMI/ISO 14971 Third Edition 2019-12 *Medical devices—Application of risk management to medical devices.*

133	irreversible impairment or damage to a body structure or function, excluding trivial
134	impairment or damage. ¹⁶
135	• Task: One or more user interactions with a medical device to achieve a desired
136	result. ¹⁷
137	• Use environment: Actual conditions and setting in which users interact with the
138	medical device. ¹⁸
139	• Use error: User action or lack of action that was different from that expected by the
140	manufacturer and caused a result that (1) was different from the result expected by the
141	user and (2) was not caused solely by device failure and (3) did or could result in
142	harm.
143	• Use safety: How safe a device is when used or the extent to which risks of harm
144	resulting from use error for medical devices have been either reduced to an acceptable
145	level or eliminated completely.
146	• User: Person interacting with (i.e., operating or handling) the medical device. ¹⁹
147	• User interface: Means by which the user and the medical device interact. ²⁰
148	• Use-related risk: Combined probability, occurrence, and severity of harm for a given
149	aspect of device use or for the overall use of a device. ²¹
150	• Use-related risk analysis: Systematic use of available information to identify use-
151	related hazards and to estimate the use-related risk.
152	

IV. Risk-based approach to human factors engineering information in marketing submissions

155 The purpose of including human factors engineering information in a marketing submission is to 156 help the manufacturer meet the applicable legal standard by demonstrating that the user interface

157 of the device is appropriate for the intended users, uses, and use environments. This section uses

158 flowcharts, tables, and text to guide submitters through a risk-based approach to recommend

what human factors engineering information a submitter should include in their marketing

- 160 submission.
- 161

162 FDA refers to this risk-based approach as the Human Factors (HF) Submission Category.

- 163 Submitters should use the flowchart in
- 164 **Figure 1** and use its companion text to answer the questions posed at each decision point to

165 determine which HF Submission Category is appropriate to support their marketing submission.

¹⁶ See 21 CFR 803.3(w).

¹⁷ ANSI/AAMI/IEC 62366-1:2015+AMD1:2020 Medical devices—Part 1: Application of usability engineering to medical devices.

¹⁸ Ibid.


¹⁹ ANSI/AAMI/IEC 62366-1:2015+AMD1:2020 Medical devices—Part 1: Application of usability engineering to medical devices.

²⁰ ANSI/AAMI/IEC 62366-1:2015+AMD1:2020 *Medical devices—Part 1: Application of usability engineering to medical devices*. Examples include packaging, labeling, training materials, physical controls, display elements, alarms, and logic of operation of each device component.

²¹ ANSI/AAMI HE75:2009/(R)2018: Human factors engineering - Design of medical devices.

Draft – Not for Implementation

- 166 This flowchart is based on the device's indications for use and the use-related risk analysis in the
- 167 context of new devices and devices for which FDA has granted marketing authorization.
- 168
- 169 FDA based the HF Submission Categories on the presence of or modification to critical tasks,
- 170 considering changes to technological characteristics or the indications for use, if relevant.
- 171 Submitters should use the use-related risk analysis and the decision points described below to
- 172 help determine the HF Submission Category for their marketing submission. Submitters should
- also reference Table 1 for FDA's recommended human factors engineering information to
- 174 provide in a marketing submission after they determine which HF Submission Category their
- 175 submission falls under using
- 176 **Figure 1**.
- 177



179

- 180 Figure 1. Flowchart illustrating a risk-based approach to determine the HF Submission
- 181 Category. ²²
- 182

²² Please note that, for the purposes of this flowchart, labeling and training have been separated out from user interface in Decision Point B to ensure that these important aspects of the user interface are considered during the decision-making process. As stated previously, this guidance's definition of user interface aligns with that of ANSI/AAMI/IEC 62366-1 which includes labeling and training as subsets of the user interface.

How to determine HF Submission Category 183 Α.

184 **Decision Point A: Is it a modification to an existing device?**

- 185 Submitters should answer "Yes" to this question when their submission is for a change to a
- device that has already received marketing authorization from FDA through a 510(k). PMA. 186
- 187 HDE application, or De Novo request. Submitters should generally answer "No" if their device is
- 188 a completely new device that has not received marketing authorization from FDA. Depending on
- 189 specific facts and circumstances, submitters may be able to answer "Yes" to this question when
- 190 they are proposing to apply human factors information from one of their own legally marketed
- 191 devices to a subject device that has the same or a similar user interface.

192 **Decision Point B: Is there a change to any of the following:**

- 193 • User interface; 194 Intended device users; • 195 • Intended device uses; 196 Intended use environment(s): • 197 • Training; or 198
 - Labeling? •
- 199 200 This question applies to only modified devices and is intended to assess whether there have been any proposed changes that affect the human factors assessment. If the answer to this question is 201 202 "No," then the level of information would fall into HF Submission Category 1; however, if the
- answer is "Yes," then the submitter should proceed to Decision Point C. 203

204 Decision Point C: Based on the use-related risk analysis, are there:

205 206

207

208

- **New devices only:** Critical tasks?²³ •
- **Modified devices only:** New critical tasks introduced or are existing critical tasks • impacted?

The use-related risk analysis incorporating risk analysis approaches such as Failure Mode and 209 210 Effects Analysis (FMEA), analysis of known use problems, and formative evaluation should be referenced to answer this question.²⁴ For modified devices, FDA recommends that submitters 211 consider the use-related risk analysis on the final finished device and not just modifications to 212 213 the device. This recommendation is intended to provide a holistic assessment of any critical tasks

- 214 that could be impacted upstream or downstream from the altered device-user interface
- 215 component.
- 216

²³ For more information on how FDA recommends identifying and categorizing user tasks, leading to a list of critical tasks, see the FDA guidance document "Applying Human Factors and Usability Engineering to Medical Devices," available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applyinghuman-factors-and-usability-engineering-medical-devices.

²⁴ For more information on how FDA recommends using risk analysis approaches, analysis of use problems, and formative evaluation, see the FDA guidance document "Applying Human Factors and Usability Engineering to Medical Devices," available at https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/applying-human-factors-and-usability-engineering-medical-devices.

Draft – Not for Implementation

217 Each identified critical task should be connected to the use-related risk analysis. When 218 determining if a critical task has been affected by a change to the device-user interface, we 219 recommend considering if those changes influence the cognitive and/or visual perception or the 220 physical interaction between the user and the device. A reduction or increase in the steps to 221 execute a critical task may be considered as affecting the critical task. 222 223 If there are no critical tasks for a new device, or no new critical tasks introduced, and no 224 impacted critical tasks for a modified device based on the use-related risk analysis, the answer to 225 this question is "No," and the level of information would fall into HF Submission Category 2. 226 If the answer is "Yes," then the level of information would fall into HF Submission Category 3. 227 228 What to include in a marketing submission based on HF 229 **B**. **Submission Category** 230 Using the flowchart in 231 232 Figure 1 and its companion text to determine the HF Submission Category, manufacturers 233 should include the following human factors information in marketing submissions: 234 235 HF Submission Category 1. Provide conclusion and high-level summary of HF evaluation: 236 The submission should include a statement justifying that the device modifications do not affect 237 the human factors considerations of the modified device and leverage, if applicable, previous 238 human factors engineering evaluations to provide the conclusion and high level summary. See 239 Table 1 for the suggested submission content for devices that fall into HF Submission Category 240 1. 241 242 HF Submission Category 2. Provide rationale in submission for why: there are no critical 243 tasks (new devices only); or there are no new critical tasks introduced and/or no changes 244 that impact critical tasks (modified devices only): The submitter should submit a rationale that 245 clearly describes the basis of their decision that there are no critical tasks for a new device, or no 246 new critical tasks introduced, and no impacted critical tasks for a modified device. This rationale 247 should be based on the decision-making noted in Section IV.A that takes the submitter through 248 each decision point. See Table 1 for the suggested submission content for devices that fall into 249 HF Submission Category 2. 250 251 HF Submission Category 3. Provide a human factors engineering report that includes 252 validation testing addressing: critical task(s) (new devices only; see Table 2); or new critical 253 task(s) introduced or existing critical task(s) impacted by change (modified devices only; 254 see Table 3): A comprehensive human factors engineering report that includes all elements of a 255 human factors engineering report described in Section IV of this guidance should be submitted to FDA for marketing submissions in HF Submission Category 3. Please note that if critical tasks 256 257 are impacted for a modified device, but existing risk control measures remain acceptable, you 258 should provide your rationale in your submission as part of the human factors information.

259

260 Table 1. Recommended minimum human factors information that should be provided for a

261 marketing submission based on HF Submission Category

Recommended information (Report section numbers from Section V below)		HF Submission Category		
	1	2	3	
Conclusion and high-level summary (Section 1)	✓	✓	\checkmark	
Descriptions of:				
• Intended device users, uses, use environments, and training				
(Section 2)		\checkmark	\checkmark	
• Device-user interface (Section 3)				
• Summary of known use problems (Section 4)				
Preliminary activities				
• Summary of preliminary analyses and evaluations (Section 5)			v	
Use-related risk analysis				
• Analysis of hazards and risks associated with use of the device				
(Section 6)			v	
• Identification and description of critical tasks (Section 7)				
Details of validation testing of final design (Section 8)			\checkmark	

262

263 Table 2. Example tabular format for the use-related risk analysis

Use- related risk analysis Task #	User Task	Possible use error(s)	Potential hazards and clinical harm	Severity of harm	Critical Task (Y/N)	Risk Mitigation Measure(s) ²⁵	Validation method for effectiveness of risk mitigation measure ²⁶
Task #1							
Task #2							

264

²⁵ For example, such risk mitigation measures could include user interface design features, labels, instructions for use, or training.

²⁶ For example, such validation methods could include human factors testing or simulated use scenario.

Draft – Not for Implementation

Table 3. Example tabular format for the comparative use-related risk analysis

Existing Device						Modified Device			
URRA Task #	User Task	Possible use error(s)	Potential hazards and clinical harm	Severity of harm	Critical task (Y/N)	Comparison of use task description to existing device	Labeling content and/or design change differences	Comparison of proposed risk mitigation measure to existing device	Submitter's comparison comments
Task #1									
Task #2									

266

267 V. Recommended content of human factors information in 268 marketing submissions

269 A manufacturer's internal documentation of risk management, human factors engineering testing

270 (when applicable), and design optimization processes can help provide evidence, where

appropriate, that the needs of the intended users were considered in the design and that the device

is safe and effective for the intended users, uses, and use environments. The Quality System
 Regulation (21 CFR part 820) requires that manufacturers of certain finished devices verify and

validate device design, review and approve changes to device design, and document changes and

approvals in the design history file (21 CFR 820.30). FDA recommends that human factors

information be maintained by the manufacturer regardless of whether it is submitted to FDA.

277 Manufacturers must keep records to the extent required under applicable law, including the

278 Quality System Regulation (e.g., 21 CFR 820.30(j)), and these (and other) records must generally

279 be made available to an FDA investigator upon request (see section 704(e) of the Federal Food,

- 280 Drug, and Cosmetic Act).
- 281

282 This section describes the HF information that may be appropriate for submission to FDA in a

- 283 marketing submission when one is required.²⁷ This human factors engineering information
- 284 describes how the human factors engineering process was applied during the development of a
- 285 medical device. Human factors engineering information should summarize the evaluations
- 286 performed. Such information does not typically include all raw data from a human factors

²⁷ This guidance is not intended to address whether or not a 510(k) or a PMA supplement is required for changes that may involve a human factors engineering analysis. Manufacturers should apply the applicable regulatory criteria in 21 CFR 807.81 or 21 CFR 814.39 to determine whether a 510(k) or PMA supplement should be submitted. For more information, see the FDA guidances "Deciding When to Submit a 510(k) for a Change to an Existing Device," available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-change-existing-device, "Deciding When to Submit a 510(k) for a Software Change to an Existing Device," available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-device, or "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process," available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-device, or "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process," available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-devices-subject-premarket-approval-pma-supplement-decision-making-process.</

Draft – Not for Implementation

287 validation test. The information should discuss the safety-related human factors engineering

288 considerations, processes, issues, resolutions, and conclusions. The information should describe

- 289 the identification, evaluation, and final assessment of all use-related hazards from using the 290 device.
- 291

292 Documents or analyses that are part of the human factors engineering process should be included 293 in the human factors engineering information provided in a marketing submission. This includes

294 portions of risk analyses focusing on user interactions with the device and specific risk analysis

295 processes, results, and conclusions. Such information can also reference materials relevant to the

296 human factors engineering process in other parts of the submission. A recommended structure

297 for this human factors engineering information is further described below:

298

299 Section 1: Conclusion and high-level summary

- Submitters should begin with a conclusion stating whether the user interface of the device has 300
- 301 been found to be adequately designed for the intended users, uses, and use environments and
- 302 whether new human factors testing was conducted to support this conclusion. FDA recommends
- 303 that submitters begin with a high-level summary of the human factors engineering assessment

304 (e.g., use-related risks), including the underlying rationale for conducting the assessment, and a

305 summary of the human factors engineering processes conducted (e.g., human factors engineering analyses and evaluations, device-user interface modifications and validation testing) and analysis

306 307 of the results.

308 When applicable, this section should discuss any remaining residual use-related risks after

309 human factors validation testing. Submitters should describe why further risk mitigation is not practicable based on a benefit-risk analysis²⁸ for the device. 310

311

326

312 Section 2: Descriptions of intended device users, uses, use environments, and training 313 This section should include:

- 314 • A description of the intended user population. If there is more than one distinct user 315 population, each population should be described. The description should include 316 meaningful differences in capabilities or use responsibilities between user populations 317 that could affect their interactions with the device. This includes lay and healthcare 318 professional users who might use the same device to perform different tasks or 319 different types of professionals who might perform different tasks on the device; 320 A summary of the device's intended use; • A summary of the device's operational context of use and critical aspects of device 321 • 322 operation, including: 323 Whether users should or must be trained by a healthcare professional prior to • 324 device use: 325
 - How the device is used across clinical applications; and
 - Set up, maintenance, cleaning, and reprocessing information. •

²⁸ For the purposes of this guidance, FDA uses the term "benefit-risk analysis" consistent with ANSI/AAMI/ISO 14971: 2019 Medical devices—Application of risk management to medical devices.

Draft – Not for Implementation

327 328 329 330 331	 A summary of the intended use environments (e.g., hospital, medevac vehicle, home use) and the characteristics of those environments (e.g., glare, vibration, ambient noise, high levels of activity) that could affect user interactions with the device; and A description of any training users would receive. A sample of the training materials such as a video, presentation slides, or a pamphlet may be appended.
332	
333	Section 3: Description of device-user interface
334	When applicable, this section should include:
335	• A graphical representation (e.g., photographs, illustrations, line drawings) of the
336	device and its user interface. This should depict the overall device and all components
337	of the user interface with which the user will interact (e.g., display and function
338	screens, alarm speakers, controls, keypads, dedicated buttons, doors, components to
339	be connected, retaining clips);
340	• A written description of the device user interface;
341	• A copy of the labeling that will be provided to the user with the device (e.g.,
342	instructions for use, user manual, quick-start guides, packaging);
343	• An overview of the operational sequence of the device and the user's expected
344	interactions with the user interface. This should include the sequence of user actions
345	performed to use the device and resulting device responses, when appropriate; and
346	• For modified devices, consider providing information comparing the subject and
347	existing devices (see Table 4 for an example format).
348	entening actives (see Fuere i for un entening remain).
349	Table 4. Example tabular format for the comparison of the modified device user interface
272	Table 4. Example tabular for mat for the comparison of the mounted device user interface

350 to the existing device

Modification description	Image of existing device-user interface component	Image of modified device-user interface component	Description of the modification made to the modified device
Modification #1			
Modification #2			

351

352 Section 4: Summary of known use problems

353 This section should describe all known use problems for previous models of the same device (as

applicable) or with similar types of devices (e.g., predicate devices). FDA recommends that

355 submitters state that there are no known use problems, if applicable. For a device that has been

356 modified specifically in response to use problems in the field, this section should discuss those

357 problems and the device modifications.

358

359 Section 5: Summary of preliminary analyses and evaluations

360 This section should identify the preliminary analysis and evaluation methods used (e.g., specific

361 analysis techniques, formative evaluations), summarize the key results of those analyses and

362 evaluations, describe modifications made to the user interface design in response, and discuss the

363 key findings that informed the protocol development for the human factors validation test.

364

Draft – Not for Implementation

365 Section 6: Analysis of hazards and risks associated with use of the device

This section of final jois of final us and fishs associated with use of the device This section should include the use-related risk analysis document and/or comparative task analysis, as applicable. This is typically an excerpt from the comprehensive risk analysis that contains all use-related hazards and risks identified through the preliminary analyses and evaluations, including those associated with potential use errors. The use-related risk analysis document is intended to be a living document; updates should be made to identified risks and hazards throughout the device design process. FDA believes it can be useful to organize this information in a tabular format. An example tabular format is provided in Table 2. This example

372 information in a tabular format. An example tabular format is provided in Table 2. This example tabular format is p

374 with your device. For modified devices in HF Submission Category 3, the submitter should

375 provide a comparative task analysis (see example tabular format in Table 3) comparing the 376 modified device use-related risk analysis with the existing device use-related risk analysis.

377

378 If you determine that a device change resulting in a modification to any task, associated harm,

and/or risk mitigation measure does not merit new HF validation test data to support the device'suse safety, please provide a rationale.

381

382 Section 7: Identification and description of critical tasks

383 This section should:

- Explain the process followed to identify the critical tasks based on the use-related risk analysis document. Since critical tasks are determined by the severity of the potential harm, FDA recommends that the submitter describe the levels of severity being used and use a reference when appropriate. For example, if the submitter is using a qualitative five-level severity rating from a voluntary consensus standard (e.g., ISO 14971²⁹), this section should include a table of severity levels with descriptions of each level and reference the applicable standard; and
- List and describe the critical tasks. For HF Submission Category 3, the submitter
 should provide a separate table highlighting the new critical tasks if relevant and
 rationale for why the task does not merit new HF validation test data to support the
 device's use safety. The submitter should also describe each use scenario included in
 the human factors validation testing and list the critical and non-critical tasks that
 constitute each use scenario.

397 398 When modifying an existing device, FDA recommends that submitters compare the new device 399 user interface to their own existing device in their marketing submission. FDA recommends 400 completing this comparison in a tabular format. An example tabular format is provided in Table 401 4. In addition to the use-related risk analysis document for the entire device, submitters should 402 include a subset of the use-related risk analysis that isolates tasks and risks associated with the 403 proposed modifications made to the device. FDA recommends including photographic images of 404 the device-user interface components that were modified, including modifications to labeling 405 such as warning statements in an instructional manual. Submitters should list any critical tasks 406 affected by the modification(s). Submitters should also discuss whether the risk associated with 407 the modification is acceptable and assess whether the proposed changes warranted human factors

²⁹ ANSI/AAMI/ISO 14971: Medical devices—Application of risk management to medical devices.

Draft – Not for Implementation

validation testing. As stated in the Human Factors Guidance,³⁰ the validation test may be limited 408

- 409 to assessment of those aspects of users' interactions and tasks that were affected by the design
- 410 modifications. 411

412 Section 8: Details of HF validation testing of final design

- 413 This section should summarize all HF validation activities conducted. In addition to test results,
- 414 this section should have a comprehensive analysis of all use errors and problems that occurred
- 415 that could have resulted in harm in real-world use, a description of all design modifications made
- 416 to the user interface in response to the test results, and a benefit-risk discussion. A full test
- 417 protocol and a sample of all scripts and forms used in the testing should be appended. Submitters
- 418 should provide a residual risk analysis and the rationale for why existing mitigation controls are 419 acceptable. While elimination of all residual risks may not be practicable, submitters should have
- 420 evidence of a systematic analysis of use errors and mitigations of use-related risks.³¹ Submitters
- 421 should reevaluate risk control and mitigation measures to identify other means to reduce risk
- 422 when it is determined that the residual risks are unacceptable.
- 423

VI. Examples 424

- 425 The following are hypothetical examples of scenarios intended to illustrate FDA's risk-based 426 approach to determine the HF Submission Category using the flowchart in
- 427 Figure 1³² and its companion text. Based on the HF Submission Category, FDA's recommended
- HF information to support the marketing submission is outlined for each scenario. These 428
- 429 examples do not account for every submission type nor the human factors information that may
- 430 be appropriate for every situation. Additionally, the examples describing modifications to an
- 431 existing device are based on an assumption that a manufacturer has already determined that it
- 432 needs to submit a new marketing submission. Therefore, these examples are not intended to
- 433 interpret when a new marketing submission is required. In addition, these examples are not
- 434 intended to comprehensively represent what should be included in a marketing submission for a 435 new or modification to an existing device.
- 436

437

Modification to an existing 510(k)-cleared device А.

438 Example A.1.

- 439
- Scenario: A submitter currently has marketing authorization for a gastrointestinal lesion software detection system³³ in a cleared 510(k). The device is a computer-assisted detection 440 441 device used in conjunction with endoscopy for the detection of abnormal lesions in the

https://www.accessdata.fda.gov/cdrh_docs/pdf20/DEN200055.pdf. The publication of this classification in the Federal Register and codification in the Code of Federal Regulations is currently pending.

³⁰ https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-andusability-engineering-medical-devices.

³¹ For example, see Appendix C of "Applying Human Factors and Usability Engineering to Medical Devices."

³² Please refer to footnote 20 for clarification on why labeling and training are listed separately from user interface for the purposes of this flowchart.

³³ Gastrointestinal lesion software detection systems are classified under 21 CFR 876.1520 and are subject to the special controls established in the reclassification order, available at

Draft – Not for Implementation

gastrointestinal tract. The submitter has proposed to modify the computer-assisted detection
algorithm such that a new 510(k) was submitted. The algorithm modifications improve the
system's ability to assist in detection of lesions and does not change any aspects of the
device-user interface.

- 446 Decision Point A: Is it a modification to an existing device?
 447 Yes. The submitter is modifying their own existing 510(k)-cleared device and using that
 448 device as the predicate device.
- 448 449

452

453

454

456

450 **Decision Point B: Is there a change to any of the following:**

- 451 User interface;
 - Intended device users;
 - Intended device uses;
 - Intended use environment(s);
- 455 Training; or
 - Labeling?

No. The changes to the algorithm do not impact any aspect of the device-user interface. The
intended users, uses, and use environments remain the same and in this instance, changes to
the algorithm do not include modifications to the labeling or training programs.

- 460
- Analysis: The recommended HF information in this marketing submission is defined by HF
 Submission Category 1. The submitter should include a statement justifying that the device
 modifications do not affect the human factors considerations of the modified device and the
 conclusion and high level summary of HF evaluation.
- 465

481

482

466 Example A.2.

467 Scenario: A submitter currently has marketing authorization for a gas machine for anesthesia 468 in a cleared stand-alone device 510(k) submission. The gas machine for anesthesia is 469 intended for use in the hospital environment and includes a touch screen graphical user 470 interface (GUI) and control knobs to regulate gas flow. The submitter requests 510(k)-471 clearance for a modification to the internal gas valving system and included in their 510(k) 472 labeling changes to reflect the modification. There are no changes to the apparent flow 473 settings from this internal change. Any modifications regarding calculated flow rates are 474 made in software settings.

475 Decision Point A: Is it a modification to an existing device?

- 476 Yes. The submitter is modifying their own existing 510(k)-cleared device and using that
 477 device as the predicate device.
- 478 **Decision Point B: Is there a change to any of the following:**
- User interface;
- 480 Intended device users;
 - Intended device uses;
 - Intended use environment(s);
- 483 Training; or

	D raft – Not for Implementation
404	
484 485	• Labeling? Yes. The labeling (instructions manual) was changed to describe the modification to the
486	internal gas valving system. This change does not impact any external user interface
487	component on the device itself. There are no changes to the intended device users, uses,
488	intended use environment, or training because there are no such changes to the indications
489	for use.
490	Decision Point C: Based on the use-related risk analysis, are there:
491	 New devices only: Critical tasks?
492	 Modified devices only: New critical tasks introduced or are existing critical
493	tasks impacted?
494	No. Even though the labeling (instructions manual) has changed, this change does not impact
495	how the intended user is expected to interact with the device because the user is not intended
496	to directly interact with the gas valving system, since it is an internal component. There are
497	no changes that influence the cognitive and/or visual perception or the physical interaction
498 499	between the user and the device. Therefore, there are no new critical tasks introduced, nor are
499 500	existing critical tasks impacted.
500 501	Analysis: The recommended HF information in this marketing submission is defined by HF
501	Submission Category 2. The submitter should provide a rationale that clearly describes the
502	basis of their decision that there are no new critical tasks introduced, and no impacted critical
504	tasks for their modified device.
505	
506	Example A.3.
507	Scenario: In addition to the change described in Example A.2, the submitter also requests
508	510(k) clearance to change the font size from 12 to 14 point on the text displayed on the
509	graphical user interface (GUI) of the gas machine for anesthesia, along with a proportional
510	increase in the screen's physical size. The submitter is also making associated software
511	changes to address the proposed change in the font size. The GUI menu does not change in
512	terms of selection layout and contains the same icons representing different intended actions.
513	Decision Point A: Is it a modification to an existing device?
514	Yes. The submitter is modifying their own existing 510(k)-cleared device and using that
515	device as the predicate device.
51(Desision Deine D. L. disease of the second of the following
516	Decision Point B: Is there a change to any of the following:
517	User interface; Intended device users:
518 510	Intended device users; Intended device users;
519 520	 Intended device uses; Intended use environment(c);
520	 Intended use environment(s); Training or
521	• Training; or
522	• Labeling?
523	Yes. There are changes to the user interface from the software changes because the user is

524 intended to directly interact visually with the words on the touch screen GUI, which the

Draft – Not for Implementation

525 submitter states is the only part of the device being modified. There are no changes to the 526 intended device users, uses, intended use environment, training, or labeling.

527

529

530

Decision Point C: Based on the use-related risk analysis, are there: 528

- New devices only: Critical tasks?
- Modified devices only: New critical tasks introduced or are existing critical • tasks impacted?

531 No. Even though the user interface (GUI) was changed to include larger text font and a larger 532 screen display, this change does not impact how the intended user is expected to interact with 533 the device because the same textual information is being presented in the same layout and format. The text size change was assessed to introduce no negative influence on the cognitive 534 535 and/or visual perception or the physical interaction between the user and the device. In this 536 case, the submitter can choose to provide formative data and/or literature supporting this 537 conclusion. Therefore, there are no new critical tasks introduced, nor are existing critical 538 tasks impacted.

539

540 Analysis: The recommended HF information in this marketing submission is HF 541 Submission Category 2. The submitter should provide a rationale (e.g., analysis of a 542 literature review for acceptable font size) that clearly describes the basis of their decision that 543 there are no new critical tasks introduced, and no impacted critical tasks for their modified 544 device.

545

546 Example A.4.

547 Scenario: The submitter requests to change the GUI of the gas machine for anesthesia 548 described in Example A.2. The proposed changes consist of changing textual menu selection 549 items to icons (i.e., graphics). In addition, the submitter requests a change from the physical 550 knob interface with discrete values for gas flow control to a digital slider with continuous 551 values within a pre-specified range that became an added feature to the touch screen GUI. 552 Based on these changes, the submitter updated the labeling, including the user manual and 553 instructions for use, and training.

554

561

562

563

564

555 Decision Point A: Is it a modification to an existing device?

- 556 Yes. The submitter is modifying their own existing 510(k)-cleared device and using that
- 557 device as the predicate device.

558 Decision Point B: Is there a change to any of the following:

- 559 User interface; • 560
 - Intended device users;
 - Intended device uses;
 - Intended use environment(s);
 - Training; or
 - Labeling?

565 Yes. There are changes to the user interface because the user directly interacts visually with 566 the icons and controls on the touch screen GUI. There is also a change in the way the user 567 controls the gas flow. There are no changes to the intended device users, uses, or intended

Draft – Not for Implementation

568 use environment. Both the submitter's training and labeling have changed based on the 569 changes to the touch screen GUI.

570

573

- Decision Point C: Based on the use-related risk analysis, are there: New devices only: Critical tasks?
- 571 • 572
 - Modified devices only: New critical tasks introduced or are existing critical • tasks impacted?

574 Yes. There are several critical tasks associated with the main touch screen GUI of the gas 575 machine for anesthesia, such as setting the ventilation mode, setting tidal volume and 576 inspiratory pressure, and setting alarms. Changing the GUI to include only icons instead of text for menu selections may impact the ability of the user to comprehend the correct 577 578 selection. There are also critical tasks associated with setting and controlling the gas flow to 579 the patient. The interface for gas flow control changed from a physical knob to a digital slider 580 on the touch screen interface, which impacts the physical interaction the user might have 581 with the gas flow control. Although the same information is being conveyed, it is displayed 582 in a different layout and format compared to the predicate.

583

584 Analysis: This requested change would be considered HF Submission Category 3. The 585 submitter should submit test results and analysis from a new HF validation study for the 586 subject device in an HF Report. The HF Report should include the use-related risk analysis, 587 along with the information referenced in Table 3.

588 589

Modification to an existing PMA-approved device **B**.

590 **Example B.1.**

591 Scenario: An implantable infusion pump has a physician programmer and both have been 592 approved as a standalone device through the PMA process. The approved physician 593 programmer is a personal digital assistant (PDA) device, with a monochrome screen and 594 physical buttons to control scrolling and menu selection. The submitter requests approval in a 595 PMA Supplement for a modification to the reservoir volume of the infusion pump. This 596 proposed change does not result in any change to medication concentration or dosing 597 calculation. The software is being updated to allow for the proposed volume change. The 598 proposed modifications, including the software changes, have no direct effect on the device 599 with which a physician or patient directly interact.

- 600 **Decision Point A: Is it a modification to an existing device?**
- 601 Yes. The submitter is modifying their own existing PMA-approved device.
- 602

604

605

608

609

- 603 **Decision Point B: Is there a change to any of the following:**
 - User interface;
 - Intended device users:
- 606 • Intended device uses: 607
 - Intended use environment(s);
 - Training; or •
 - Labeling?

Draft – Not for Implementation

- 610 Yes. The labeling (instructions manual) was updated to specify the change in the reservoir611 volume.
- 612 Decision Point C: Based on the use-related risk analysis, are there:
 - New devices only: Critical tasks?
 - Modified devices only: New critical tasks introduced or are existing critical tasks impacted?

No. There are critical tasks that could in some circumstances be impacted by a change in the
reservoir volume, including medication concentration and the dosing that are related to drug
delivery to the patient. In this case, the medication concentration and dosing remained the
same, even with the change in reservoir volume. Therefore, no critical tasks were impacted
by the change in reservoir volume.

621

613

614

615

- 622 Analysis: The recommended HF information in this marketing submission is HF
- Submission Category 2. The submitter should provide a rationale (e.g., discussion of how
 the change in total reservoir volume does not affect critical tasks such as setting
 concentration or calculating dosage) that clearly describes the basis of their decision that
 there are no new critical tasks introduced, and no impacted critical tasks for their modified
- 627

628

629 Example B.2.

device.

630 **Scenario:** Like 0, an implantable infusion pump has a physician programmer and both have 631 been approved through the PMA process. The approved physician programmer is a PDA 632 device, with a monochrome screen and physical buttons to control scrolling and menu 633 selection. The submitter requests approval in a PMA Supplement for a modification to the 634 physician programmer from the approved monochrome PDA to a mini-tablet computer with 635 a touch screen user interface. The display on the tablet computer will feature a full color 636 display and new icons for menu functions.

- 637 **Decision Point A: Is it a modification to an existing device?**
- 638 Yes. The submitter is modifying their own existing PMA-approved device.639
- 640 **Decision Point B: Is there a change to any of the following:**
- User interface;
 - Intended device users;
 - Intended device uses;
 - Intended use environment(s);
 - Training; or
 - Labeling?
- Yes. The introduction of new icons, color selection and display, and new menu orientation,
 has changed the user interface. Due to these changes, the submitter is also proposing to
 change the relevant training and labeling (instructions manual).

650

642

643

644

645

646

	D raft – Not for Implementation
651	Decision Point C: Based on the use-related risk analysis, are there:
652	• New devices only: Critical tasks?
653	• Modified devices only: New critical tasks introduced or are existing critical
654	tasks impacted?
655	Yes. In this case, the submitter evaluated the existing critical tasks, and some were impacted.
656	Dose calculation function is impacted by additional (new) icon access on new home screen
657	for unit selection and confirmation. Additional steps and workflow with new icon could
658	cause user negative transfer of experience and lead to delay of therapy.
659	
660	Analysis: The recommended HF information in this marketing submission is HF
661	Submission Category 3. The submitter should submit test results and analysis from a new
662	HF validation study for the subject device in an HF Report. The HF Report should include
663	the use-related risk analysis, along with the information referenced in Table 3.
664	
665	Example B.3.
666	Scenario: A submitter has an approved PMA for a stent with a balloon catheter delivery
667	system. The submitter is requesting approval for a new stent under a new PMA that has a
668	different stent design and coating. The new stent uses the same balloon catheter delivery
669	system as the submitter's own PMA-approved stent. The submitter is proposing to leverage
670	the previous HF validation test results for the balloon catheter delivery system.
671	Decision Point A: Is it a modification to an existing device?
672	Yes. The submitter is using their own existing PMA-approved balloon catheter delivery
673	system with a new stent.
674	Decision Point B: Is there a change to any of the following:
675	• User interface;
676	• Intended device users;
677	• Intended device uses;
678	 Intended use environment(s);
679	• Training; or
680	• Labeling?
681	No. Even though the submitter has submitted a new PMA, in this case, the user-interface of
682	the balloon catheter delivery system is the same as that used in the approved PMA. The only
683	changes to the product are the stent design and coating, which are not user-interfacing and
684	are based on the submitter's approved PMA. The submitter evaluated the critical tasks, and
685	none of them were impacted by the change in stent design and coating. The submitter can
686	leverage the previous HF validation test results in their new PMA.
687	
688	Analysis: The recommended HF information in this marketing submission is HF
689	Submission Category 1. The submitter should include a statement justifying that the device
690	modifications do not affect the human factors considerations of the modified device and the
601	an almain and high land manager of UE analystica

- 691 692 693 conclusion and high level summary of HF evaluation.

694 C. New devices

695 Example C.1.

696 Scenario: In an alternate scenario to Example B.3, the submitter is proposing to introduce
697 the new stent as described above, along with a new balloon catheter delivery system that has
698 a different design from the PMA-approved system.

699 Decision Point A: Is it a modification to an existing device?

No. The submitter is submitting a new PMA based on a new design of the catheter delivery
 system with a new stent. The submitter should proceed to Decision Point C.

702 **Decision Point C: Based on the use-related risk analysis, are there:**

- 703
- 704 705

730

731

732

- New devices only: Critical tasks?
- Modified devices only: New critical tasks introduced or are existing critical tasks impacted?

Yes. The submitter has determined based on the use-related risk analysis that there arecritical tasks associated with the subject device.

Analysis: The recommended HF information in this marketing submission is HF
Submission Category 3. The submitter should submit test results and analysis from a new
HF validation study for the subject device in an HF Report. The HF Report should include
the use-related risk analysis, along with the information referenced in Table 3.

713714 Example C.2.

715 Scenario: The submitter submits a 510(k) to request clearance for a new portable fingertip 716 oximeter intended for spot checking oxygen saturation of arterial hemoglobin of adult 717 patients in professional healthcare facilities and the home. This is the first portable oximeter 718 device developed by the submitter. Therefore, the submitter uses a predicate device from a 719 different submitter. The subject device does not include any alarms or additional information 720 interpreting the oxygen saturation, nor is it intended for life supporting or life-sustaining 721 functions. The user of the device places the sensor on a finger and then reads the oxygen 722 saturation values calculated by the device. The submitter compares their device with the 723 predicate device to show the indications for use, use environment, and users are the same 724 between the two devices.

725 Decision Point A: Is it a modification to an existing device?

No. The submitter has manufactured a new device. For purposes of demonstrating substantial
equivalence, the submitter has identified as a predicate a device from another device
manufacturer. The submitter should proceed to Decision Point C.

729 Decision Point C: Based on the use-related risk analysis, are there:

- New devices only: Critical tasks?
- Modified devices only: New critical tasks introduced or are existing critical tasks impacted?
- No. The submitter determined through their use-related risk analysis that the action of placing the sensor on a user's finger and reading the oxygen saturation values could not

Draft – Not for Implementation

cause serious harm to the user/patient. The submitter further justifies this conclusion by
stating the device is used as a spot-check and there are no alarms or additional information
interpreting the results from the device.

738

739 Analysis: The recommended HF Submission Category in this marketing submission is HF

740 **Submission Category 2**. The submitter should provide a rationale for why there are no

741 critical tasks.